CORONAVIRUS INFO PROVIDED BY DR. JIM HARRIS – 04/20/2021
HELLO, NYT DASHBOARD TODAY:
(J. Harris: It appears that the “surge” did not hit Texas, supposedly due to vaccinations and continued mask wearing by most people, vaccinated or not.
Perhaps, I should consider apologizing to Governor Abbot —– Naw. We got lucky.)
FROM THE WASHINGTON POST
The pause of the Johnson & Johnson vaccine may be lifted Friday, according to Anthony S. Fauci, the nation’s top infectious-disease expert. Fauci explained to NBC News’s “Meet the Press” on Sunday that a “warning or restriction or risk assessment” may be added to the vaccine. The Centers for Disease Control and Prevention’s vaccine advisory committee plans to meet again Friday to continue its review of the J&J safety data.
MARION COUNTY WALK IN VACCINE CLINIC CLOSES DUE TO LOW TURNOUT
1. PRESS RELEASE
FDA Revokes Emergency Use Authorization for Monoclonal Antibody Bamlanivimab The US Food and Drug Administration revoked the emergency use authorization (EUA) that allowed for the investigational monoclonal antibody therapy bamlanivimab, when administered alone, to be used for the treatment of mild-to-moderate COVID-19 in adults and certain pediatric patients. Based on its ongoing analysis of emerging scientific data, specifically the sustained increase of SARS-CoV-2 viral variants that are resistant to bamlanivimab alone resulting in the increased risk for treatment failure, the FDA has determined that the known and potential benefits of bamlanivimab, when administered alone, no longer outweigh the known and potential risks for its authorized use. (FDA, 4/16/2021)
2. PRESS RELEASE
Large Clinical Trial to Study Repurposed Drugs to Treat COVID-19 Symptoms The National Institutes of Health will fund a large, randomized, placebo‑controlled Phase 3 clinical trial to test several existing prescription and over-the-counter medications for people to self-administer to treat symptoms of COVID-19. Part of the Accelerating COVID‑19 Therapeutic Interventions and Vaccines (ACTIV) public–private partnership, the ACTIV-6 trial aims to provide evidence-based treatment options for the majority of adult patients with COVID-19 who have mild-to-moderate symptoms and are not sick enough to be hospitalized. NIH will provide an initial investment of $155 million in funding for the trial. (NIH, 4/19/2021)
3. PRESS RELEASE
Experimental Antiviral for COVID-19 Effective in Hamster Study The experimental antiviral drug MK-4482 significantly decreased levels of virus and disease damage in the lungs of hamsters treated for SARS-CoV-2 infection, according to a new study from National Institutes of Health scientists. SARS-CoV-2 is the virus that causes COVID-19. MK-4482, delivered orally, is now in human clinical trials. (NIH, 4/16/2021)
4. PRESS RELEASE
NIH Trial of Anti-CD14 Antibody to Treat COVID-19 Respiratory Disease Begins A clinical trial testing the safety and efficacy of an investigational monoclonal antibody for treating people who are hospitalized with respiratory disease and low blood oxygen due to infection with SARS-CoV-2, the virus that causes COVID-19, has begun. The Phase 2 trial, called the COVID-19 anti-CD14 Treatment Trial (CaTT), is sponsored and funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. (NIH, 4/13/2021)
(J Harris: Medical science is developing drugs to treat Covid early and orally. They are also eliminating medications that were found by scientific study not to work or to be too dangerous to use. Hopefully, we won’t be caught so unprepared in the future. I do hope when good drugs are developed that they will be given names that can be remembered, pronounced, and spelled. )
AND LAST BUT NOT LEASED:
GIVE US YOUR FEEDBACK. CLICK ON “COMMENT” TO TELL US WHAT YOU THINK or use one of the alternative methods for providing feedback.
Click here to submit feedback. Let us know what you think.